Key Highlights
- Revenues were USD 380,216 against an estimate of USD 640 thousand.
- Net loss per share was USD 0.12 against an estimate of a USD 0.14 loss.
- Net loss was USD 1.38 million, compared with USD 825,539.
- Cash and cash equivalents were USD 3.63 million at September 30, 2026.
20/20 BioLabs (NASDAQ:AIDX) reported revenues of USD 380,216 for the third quarter of 2026, compared with USD 417,979 in the prior-year quarter, against an estimate of USD 640 thousand. Basic and diluted net loss per common share was USD 0.12, compared with USD 0.17, against an estimate of a USD 0.14 loss.
Net loss was USD 1.38 million, compared with USD 825,539. Net loss attributable to common stockholders was USD 1.50 million, after preferred stock dividends of USD 128,441.
Third Quarter Results
Cost of revenues was USD 283,343, compared with USD 272,913, and Gross Profit was USD 96,873, compared with USD 145,066. Sales, general and administrative expenses were USD 1.36 million, compared with USD 814,179, and Research and Development expenses were USD 123,385, compared with USD 131,060.
Total operating expenses were USD 1.49 million, compared with USD 945,239, and the operating loss was USD 1.39 million, compared with USD 800,173. Interest income was USD 14,806, compared with USD 4,181, and total other income was USD 14,806, compared with total other expense of USD 25,366. Weighted average common shares outstanding were 12,958,114, compared with 4,849,770.
Nine-Month Results
For the nine months ended September 30, 2026, revenues were USD 1.46 million, compared with USD 1.51 million, and gross profit was USD 464,484, compared with USD 474,124. Sales, general and administrative expenses were USD 4.01 million, compared with USD 2.43 million, and research and development expenses were USD 534,499, compared with USD 462,015.
The operating loss was USD 4.08 million, compared with USD 2.42 million. Interest expense was USD 539,253, the loss on change in Fair Value of Warrant Liability was USD 148,766, and the loss on issuance of a convertible note was USD 326,595. The net loss was USD 5.06 million, compared with USD 2.43 million. After a deemed dividend of USD 1.12 million on warrant modifications and preferred stock dividends of USD 304,295, the net loss attributable to common stockholders was USD 6.49 million, or USD 0.62 per share, compared with USD 0.50.
Balance Sheet and Going Concern Disclosure
Cash and cash equivalents were USD 3,633,711 at September 30, 2026, compared with USD 1,025,987 at December 31, 2025, and the company reported Working Capital of USD 1,538,409. Accounts receivable, net, were USD 173,985. Total Assets were USD 5.02 million, compared with USD 4.14 million, and total current liabilities were USD 2.49 million. Total liabilities were USD 2.85 million, compared with USD 4.16 million.
The filing discloses substantial doubt about the company's ability to continue as a going concern and states that planned activities include potential Equity raises and reverse stock splits.
20/20 BioLabs Q3 2026 Earnings: Key Takeaways
20/20 BioLabs reported third quarter 2026 revenues of USD 380,216, an operating loss of USD 1.39 million and a net loss of USD 1.38 million. Cash and cash equivalents were USD 3.63 million at September 30, 2026.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...